Soligenix (SNGX): Earnings growth forecast for next year

Soligenix, Inc. (SNGX) - corporate logo

Soligenix, Inc. (SNGX) develops patent-protected treatments for rare pathogens and lymphomas, occupying narrow market niches. Consensus earnings expectations for the n+1 period on GURU.Markets contain 37.40, which represents the current level of the indicator. While Soligenix, Inc. (SNGX) relies on government grants and biothreat partnerships, the absence of commercial sales deprives the company of pricing power in the market.

SNGX - Soligenix Inc Projected earnings per share increase next year over the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Soligenix (SNGX)

- share price and consensus valuation forecast:
Stock Price Soligenix Inc|SNGX - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization Soligenix|SNGX - Real Price to Acquire Entire Company
- book capitalization indicators:
Accounting Value per Share Soligenix|SNGX - Total Net Assets|Market Capitalization to Book Value Ratio soligenix.com|SNGX - Company Total Asset Base
- company liabilities and liquidity data:
Debt to Equity Soligenix, Inc.|SNGX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Soligenix Inc|SNGX - Company Aggregate Debt|Debt to Book Capitalization Ratio Soligenix|SNGX - Long-Term Debt Volume|Company Short-Term Debt Soligenix|Quick Liquidity soligenix.com
- earnings and market ratios statistics:
SNGX - Company Net Income|Expected Profit Soligenix, Inc.|SNGX - Price to Earnings Ratio|Forward P/E Multiple Soligenix Inc|SNGX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Soligenix|SNGX - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Soligenix|SNGX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months soligenix.com|SNGX - Earnings per share growth this year|Earnings growth forecast for next year Soligenix, Inc.
- sales volume and revenue information:
SNGX - Company Gross Revenue|Company Future Sales Volume Soligenix Inc
General company analysis:SNGX, Soligenix, Inc.
Core merchandise of Soligenix Inc

The consensus earnings forecast for the coming year serves as a leading indicator of market expectations, reflecting the average analyst opinion on EPS growth rates. This metric tracks shifts in fundamental momentum, allowing for the timely identification of stagnation before a price correction occurs. Assessing the EPS trend for the coming year is critical for Soligenix, Inc. (SNGX), as it reflects the commercialization potential of Riavax vaccines and the probability of securing strategic government contracts.

Competitor analysis

SMMT (Summit Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Moderna Therapeutics MRNA|Earnings growth forecast for next year PCVX|Expected earnings per share growth for next year tarsusrx.com TARS|CorMedix - Expected earnings per share growth for next year|Projected earnings per share increase next year MCRB (Seres Therapeutics Inc.)|Spero - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year SCYNEXIS, Inc. SCYX|an2therapeutics.com (ANTX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year PolyPid (PYPD)|Net earnings per share growth forecast for next year LakeShore Biopharma|Projected earnings per share growth rate for next year ITRM (Iterum Therapeutics, plc)|Net earnings per share growth forecast for next year BiomX Inc. (PHGE)|Consensus forecast of earnings per share growth for next year 60degreespharma.com|Net earnings per share growth forecast for next year Oragenics OGEN|Consensus forecast of earnings per share growth for next year opgen.com (OPGN)